What is a potential risk of using methotrexate in patients with liver disease?

Methotrexate is a medication commonly used in the treatment of various cancers and autoimmune diseases. In patients with liver disease, the metabolism and clearance of methotrexate can be significantly affected due to impaired liver function. This can lead to elevated levels of the drug in the system, resulting in a higher risk of side effects. These side effects can include hepatotoxicity, myelosuppression, and gastrointestinal issues, among others, which can be more pronounced in individuals with preexisting liver conditions.

In contrast, options discussing enhanced drug absorption, improved efficacy, or the notion of no significant risk do not accurately capture the pharmacokinetic changes and risks presented by liver disease. The compromised liver function can disrupt the normal metabolic pathways, exacerbating the toxic effects of methotrexate and thus increasing the risk of adverse effects in these patients. This understanding highlights the importance of careful monitoring and dosage adjustments when prescribing methotrexate in individuals with liver disease.